NASDAQ · LSTA
Healthcare · Biotechnology
$1.90
Down-$0.26 (-13.68%)
Updated Sep 11, 2026, 12:39 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
LSTA closed at $1.90 after 19 trading sessions, up 68.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.86 | $1.999 | $1.73 | $1.90 | 208.27K |
| Sep 8, 2026 | $1.65 | $1.89 | $1.62 | $1.86 | 252.5K |
| Sep 4, 2026 | $1.58 | $1.70 | $1.5637 | $1.65 | 33.92K |
| Sep 3, 2026 | $1.57 | $1.71 | $1.45 | $1.64 | 162.87K |
| Sep 2, 2026 | $1.52 | $1.64 | $1.45 | $1.57 | 113.61K |
| Sep 1, 2026 | $1.48 | $1.64 | $1.234 | $1.57 | 475.6K |
| Aug 31, 2026 | $1.66 | $1.66 | $1.44 | $1.49 | 243.39K |
| Aug 28, 2026 | $1.80 | $1.815 | $1.54 | $1.69 | 245.05K |
| Aug 27, 2026 | $1.76 | $1.9396 | $1.76 | $1.82 | 86.67K |
| Aug 26, 2026 | $1.76 | $1.87 | $1.75 | $1.81 | 51.73K |
| Aug 25, 2026 | $1.75 | $1.90 | $1.72 | $1.74 | 184.3K |
| Aug 24, 2026 | $1.63 | $2.00 | $1.60 | $1.76 | 1.09M |
| Aug 21, 2026 | $1.11 | $1.79 | $1.1043 | $1.55 | 7.12M |
| Aug 20, 2026 | $1.13 | $1.165 | $1.07 | $1.12 | 94.82K |
| Aug 19, 2026 | $1.11 | $1.225 | $1.08 | $1.12 | 167.48K |
| Aug 18, 2026 | $1.10 | $1.20 | $1.10 | $1.15 | 35.07K |
| Aug 17, 2026 | $1.09 | $1.1574 | $1.08 | $1.08 | 21.54K |
| Aug 14, 2026 | $1.10 | $1.15 | $1.05 | $1.09 | 24.98K |
| Aug 13, 2026 | $1.19 | $1.19 | $1.10 | $1.13 | 31.49K |
The latest Smart Investors Daily articles mentioning LSTA.
LSTA research
Company profile and research snapshot.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | Brookline Capital | Hold | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | Brookline Capital | Buy | — |
| Dec 11, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking,
Benzinga · Jul 24, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm
Benzinga · Jul 22, 2026
Lisata Therapeutics stock fell after hours after updating investors on its pending acquisition and tender offer.
Benzinga · Jun 10, 2026
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LSTA.
